Review



enzalutamide  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    MedChemExpress enzalutamide
    A fraction of PPFIA4 localizes in the mitochondria and confers increased mitochondrial function. A . KEGG pathway gene set enrichment analysis of downregulated genes in C4-2B cells with PPFIA4 knockdown. C4-2B cells were transfected with siNC or siPPFIA4 for 48 hours. Total RNA was then extracted and used to perform RNA-Seq analyses. KEGG pathway gene set enrichment analysis was carried out to examine the pathway enrichment. B . Organelle localization analysis of PPFIA4 interacting proteins by Web Gestalt ( http://www.webgestalt.org/ ). C4-2B cell lysates were immunoprecipitated with PPFIA4 antibody and resolved by SDS–PAGE. Liquid chromatography-tandem mass spectrometry analysis was performed to identify its interacting proteins. C . Localization of PPFIA4 (green) in LNCaP cell mitochondria (red) was verified by immunofluorescent staining with or without androgen deprivation. Representative images are shown with a 10-μm scale bar. Magnified images from the regions marked by rectangles in the top panel was showed in the bottom panel. Mito, mitochondria. FBS, fatal bovine serum. CSS, charcoal-stripped serum. D . The protein levels of PPFIA4 in total cell lysates (Total), cytosolic fraction (Cyto), and mitochondrial fraction (Mito) were analyzed by western blotting in LNCaP cells with or without androgen deprivation. COXIV and tubulin were used as mitochondrial and cytosolic markers. E-F . Measurement of OCR in indicated PCa cells with PPFIA4 overexpression or knockdown and treated with or without androgen deprivation and <t>enzalutamide</t> (10 μM). Representative recording of OCR during extracellular flow analysis (“Seahorse”) is shown in the up panel, and quantitative analysis of the calculated basal and maximum respiratory rates, ATP production rate and spare respiratory capacity are shown in the bottom panel. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. m, minutes. FBS, fatal bovine serum. CSS, charcoal-stripped serum. ENZ, enzalutamide. G-L . Measurement of membrane potentials, NADPH/ NADP + ratio, and ROS levels in LNCaP (G-I) and C4-2B (J-L) cells with PPFIA4 overexpression or knockdown and treated with or without androgen deprivation. ** p < 0.01, *** p < 0.001, *** p < 0.001, **** p < 0.0001. FBS, fatal bovine serum. CSS, charcoal-stripped serum. M . Cell proliferation was measured by cell counts in C4-2B cells with PPFIA4 knockdown and treated with or without ROS scavenger NAC (5 nM). Cell number was counted at the indicated time points and all the numbers were normalized to day 0. All error bars represent the SD of at least three replicates from three independent experiments. ** p < 0.01, *** p < 0.001. d, days
    Enzalutamide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 829 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/enzalutamide/product/MedChemExpress
    Average 99 stars, based on 829 article reviews
    enzalutamide - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2"

    Article Title: PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-022-02331-3

    A fraction of PPFIA4 localizes in the mitochondria and confers increased mitochondrial function. A . KEGG pathway gene set enrichment analysis of downregulated genes in C4-2B cells with PPFIA4 knockdown. C4-2B cells were transfected with siNC or siPPFIA4 for 48 hours. Total RNA was then extracted and used to perform RNA-Seq analyses. KEGG pathway gene set enrichment analysis was carried out to examine the pathway enrichment. B . Organelle localization analysis of PPFIA4 interacting proteins by Web Gestalt ( http://www.webgestalt.org/ ). C4-2B cell lysates were immunoprecipitated with PPFIA4 antibody and resolved by SDS–PAGE. Liquid chromatography-tandem mass spectrometry analysis was performed to identify its interacting proteins. C . Localization of PPFIA4 (green) in LNCaP cell mitochondria (red) was verified by immunofluorescent staining with or without androgen deprivation. Representative images are shown with a 10-μm scale bar. Magnified images from the regions marked by rectangles in the top panel was showed in the bottom panel. Mito, mitochondria. FBS, fatal bovine serum. CSS, charcoal-stripped serum. D . The protein levels of PPFIA4 in total cell lysates (Total), cytosolic fraction (Cyto), and mitochondrial fraction (Mito) were analyzed by western blotting in LNCaP cells with or without androgen deprivation. COXIV and tubulin were used as mitochondrial and cytosolic markers. E-F . Measurement of OCR in indicated PCa cells with PPFIA4 overexpression or knockdown and treated with or without androgen deprivation and enzalutamide (10 μM). Representative recording of OCR during extracellular flow analysis (“Seahorse”) is shown in the up panel, and quantitative analysis of the calculated basal and maximum respiratory rates, ATP production rate and spare respiratory capacity are shown in the bottom panel. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. m, minutes. FBS, fatal bovine serum. CSS, charcoal-stripped serum. ENZ, enzalutamide. G-L . Measurement of membrane potentials, NADPH/ NADP + ratio, and ROS levels in LNCaP (G-I) and C4-2B (J-L) cells with PPFIA4 overexpression or knockdown and treated with or without androgen deprivation. ** p < 0.01, *** p < 0.001, *** p < 0.001, **** p < 0.0001. FBS, fatal bovine serum. CSS, charcoal-stripped serum. M . Cell proliferation was measured by cell counts in C4-2B cells with PPFIA4 knockdown and treated with or without ROS scavenger NAC (5 nM). Cell number was counted at the indicated time points and all the numbers were normalized to day 0. All error bars represent the SD of at least three replicates from three independent experiments. ** p < 0.01, *** p < 0.001. d, days
    Figure Legend Snippet: A fraction of PPFIA4 localizes in the mitochondria and confers increased mitochondrial function. A . KEGG pathway gene set enrichment analysis of downregulated genes in C4-2B cells with PPFIA4 knockdown. C4-2B cells were transfected with siNC or siPPFIA4 for 48 hours. Total RNA was then extracted and used to perform RNA-Seq analyses. KEGG pathway gene set enrichment analysis was carried out to examine the pathway enrichment. B . Organelle localization analysis of PPFIA4 interacting proteins by Web Gestalt ( http://www.webgestalt.org/ ). C4-2B cell lysates were immunoprecipitated with PPFIA4 antibody and resolved by SDS–PAGE. Liquid chromatography-tandem mass spectrometry analysis was performed to identify its interacting proteins. C . Localization of PPFIA4 (green) in LNCaP cell mitochondria (red) was verified by immunofluorescent staining with or without androgen deprivation. Representative images are shown with a 10-μm scale bar. Magnified images from the regions marked by rectangles in the top panel was showed in the bottom panel. Mito, mitochondria. FBS, fatal bovine serum. CSS, charcoal-stripped serum. D . The protein levels of PPFIA4 in total cell lysates (Total), cytosolic fraction (Cyto), and mitochondrial fraction (Mito) were analyzed by western blotting in LNCaP cells with or without androgen deprivation. COXIV and tubulin were used as mitochondrial and cytosolic markers. E-F . Measurement of OCR in indicated PCa cells with PPFIA4 overexpression or knockdown and treated with or without androgen deprivation and enzalutamide (10 μM). Representative recording of OCR during extracellular flow analysis (“Seahorse”) is shown in the up panel, and quantitative analysis of the calculated basal and maximum respiratory rates, ATP production rate and spare respiratory capacity are shown in the bottom panel. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. m, minutes. FBS, fatal bovine serum. CSS, charcoal-stripped serum. ENZ, enzalutamide. G-L . Measurement of membrane potentials, NADPH/ NADP + ratio, and ROS levels in LNCaP (G-I) and C4-2B (J-L) cells with PPFIA4 overexpression or knockdown and treated with or without androgen deprivation. ** p < 0.01, *** p < 0.001, *** p < 0.001, **** p < 0.0001. FBS, fatal bovine serum. CSS, charcoal-stripped serum. M . Cell proliferation was measured by cell counts in C4-2B cells with PPFIA4 knockdown and treated with or without ROS scavenger NAC (5 nM). Cell number was counted at the indicated time points and all the numbers were normalized to day 0. All error bars represent the SD of at least three replicates from three independent experiments. ** p < 0.01, *** p < 0.001. d, days

    Techniques Used: Knockdown, Transfection, RNA Sequencing Assay, Immunoprecipitation, SDS Page, Liquid Chromatography, Mass Spectrometry, Staining, Western Blot, Over Expression, Membrane

    DS18561882 inhibits CRPC progression in vitro and in vivo. A-B . Cell proliferation and cell apoptosis assays of LNCaP cells transfected with empty vector or PPFIA4 overexpression plasmid (A) and C4-2B cells transfected with siNC or siPPFIA4 (B) with or without DS18561882 (50μM) treatment. ** p < 0.01, *** p < 0.001. d, days. C-E . Castrated mice possessing xenografts (LNCaP-Vector and LNCaP-PPFIA4) received vehicle control or DS18561882 treatment (100 mg/kg, n = 5/group, p.o.). Caliper measurements were taken twice every week to obtain tumor volume (C). Tumors were collected and weighed (D) after the mice were sacrificed. IHC staining of Ki67 (E) on tumor slide from each group is shown. ** p < 0.01, *** p < 0.001. Scale bars, 20 μm. p.o., peros. F-G . Cell proliferation (F) and cell apoptosis assays (G) of C4-2B (left) and LNCaP cells (right) treated with DMSO, enzalutamide (10 μM), DS18561882 (50 μM) alone or in combination. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. d, days. ENZ, enzalutamide. COM, combination. H-J . Castrated mice bearing xenografts (C4-2B cells) were treated with vehicle control, enzalutamide (10 mg/kg, p.o.), DS18561882 (100 mg/kg, p.o.), or in combination ( n = 5/group). Tumor volume was measured (H) and then weighed (I) when mice were sacrificed. IHC staining of Ki67 (J) on tumor slides from each group is shown. *** p < 0.001, **** p < 0.0001. Scale bars, 20 μm. p.o., peros. ENZ, enzalutamide. COM, combination
    Figure Legend Snippet: DS18561882 inhibits CRPC progression in vitro and in vivo. A-B . Cell proliferation and cell apoptosis assays of LNCaP cells transfected with empty vector or PPFIA4 overexpression plasmid (A) and C4-2B cells transfected with siNC or siPPFIA4 (B) with or without DS18561882 (50μM) treatment. ** p < 0.01, *** p < 0.001. d, days. C-E . Castrated mice possessing xenografts (LNCaP-Vector and LNCaP-PPFIA4) received vehicle control or DS18561882 treatment (100 mg/kg, n = 5/group, p.o.). Caliper measurements were taken twice every week to obtain tumor volume (C). Tumors were collected and weighed (D) after the mice were sacrificed. IHC staining of Ki67 (E) on tumor slide from each group is shown. ** p < 0.01, *** p < 0.001. Scale bars, 20 μm. p.o., peros. F-G . Cell proliferation (F) and cell apoptosis assays (G) of C4-2B (left) and LNCaP cells (right) treated with DMSO, enzalutamide (10 μM), DS18561882 (50 μM) alone or in combination. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. d, days. ENZ, enzalutamide. COM, combination. H-J . Castrated mice bearing xenografts (C4-2B cells) were treated with vehicle control, enzalutamide (10 mg/kg, p.o.), DS18561882 (100 mg/kg, p.o.), or in combination ( n = 5/group). Tumor volume was measured (H) and then weighed (I) when mice were sacrificed. IHC staining of Ki67 (J) on tumor slides from each group is shown. *** p < 0.001, **** p < 0.0001. Scale bars, 20 μm. p.o., peros. ENZ, enzalutamide. COM, combination

    Techniques Used: In Vitro, In Vivo, Transfection, Plasmid Preparation, Over Expression, Control, Immunohistochemistry



    Similar Products

    Image Search Results